JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, L.
Right arrow Articles by Haberkorn, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, L.
Right arrow Articles by Haberkorn, U.

Radioiodine Therapy of Hepatoma Using Targeted Transfer of the Human Sodium/Iodide Symporter Gene

Libo Chen1,2, Annette Altmann2, Walter Mier3, Helmut Eskerski2, Karin Leotta2, Lihe Guo4, Ruisen Zhu1 and Uwe Haberkorn2,3

1 Department of Nuclear Medicine, Shanghai Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China; 2 Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center (DKFZ) and University of Heidelberg, Heidelberg, Germany; 3 Department of Nuclear Medicine, University of Heidelberg, Heidelberg, Germany; and 4 Division of Biochemistry and Cell Biology, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, Shanghai, China


Figure 1
View larger version (9K):

[in a new window]
  		FIGURE 1.  Expression of reporter gene (luciferase) driven by albumin enhancer/promoter in different cell lines. Data are expressed as mean ± SD (n = 3).

 

Figure 2
View larger version (18K):

[in a new window]
  		FIGURE 2.  Time course of iodide uptake by MH3924A and MHmAlbhNIS cells (A) and modulation of iodide uptake by DIDS, ouabain, and sodium perchlorate (B). Data are expressed as mean ± SD (n = 3).

 

Figure 3
View larger version (16K):

[in a new window]
  		FIGURE 3.  Iodide efflux from MHmAlbhNIS cells after 1-h incubation with Na125I. Data are expressed as mean ± SD (n = 3).

 

Figure 4
View larger version (15K):

[in a new window]
  		FIGURE 4.  Survival rates (%) of MH3924A and MHmAlbhNIS cells treated with Na131I. Data are expressed as mean ± SD (n = 3).

 

Figure 5
View larger version (96K):

[in a new window]
  		FIGURE 5.  Whole-body scintigraphic images (anterior view) of ACI rats subcutaneously transplanted with hNIS-expressing (right thigh) or wild-type Morris hepatoma cells (left thigh) at 30 min (A), 2 h (B), 4 h (C), and 24 h (D) after intravenous injection of 131I–. T = thyroid; S = stomach; NIS = NIS-expressing tumor; WT = wild-type tumor.

 

Figure 6
View larger version (20K):

[in a new window]
  		FIGURE 6.  Biodistribution of radiotracer at different times after intraperitoneal administration of Na131I in ACI rats bearing MH3924A and MHmAlbhNIS tumor cells. Data are expressed as mean %ID/g ± SD (n = 3). WT = wild-type tumor (MH3924A).

 

Figure 7
View larger version (21K):

[in a new window]
  		FIGURE 7.  Antitumor effect of hNIS expression combined with radioiodide administration in ACI rats injected subcutaneously with wild-type MH3924A cells (A) or MHmAlbhNIS tumor cells (B). Data are expressed as mean ± SD (n = 5).

 




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2006 by the Society of Nuclear Medicine.